Vendor Intelligence Report: Maidihao

Published 13 Jun 2026. 21-page investigative report on who is behind Maidihao: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 9 Finnrick lab tests, Maidihao records 7 passes and 2 failures for an overall pass rate of 78%. The tested catalog is narrow: Retatrutide is the stronger lane, while Tesamorelin is materially weaker and should not be upgraded by association. Stricter grading makes the picture more cautionary because the storefront lacks verifiable lot-level COAs.

The vendor wrapper is the larger concern. Registry material ties the storefront to Shenzhen Maidihao Trading Co., Ltd., a revoked trading company whose recorded scope is electronics rather than peptides, chemicals, or research reagents. That leaves a weak accountable counterparty if an order is mislabeled, underfilled, seized, or never delivered.

Infrastructure records are more specific than a generic anonymity warning. Maidihao sits on Shop910, a cross-border storefront platform that advertises cloaking, redirect rotation, and special-goods card processing. Source-code and CDN artifacts tie the site to a sister-tenant clone pattern and borrowed factory imagery, undermining the manufacturing story without yet identifying the true filler.

Transparency gets worse at the customer-support layer: the captured contact page reused the same placeholder phone and email for multiple agents, backend chat/email fields were empty, and the site later redirected to a Shop910 admin login. For buyers, this report is product-specific rather than blanket: Retatrutide is the more defensible tested option; Tesamorelin and the untested catalog require fresh lot-specific verification.

Inside the full report:

  • Appendix A laboratory data and methodology-divergence charts for both tested products
  • Chinese registry analysis for the revoked Shenzhen Maidihao Trading Co., Ltd.
  • Shop910 source-code, CDN, cloaking, and redirect-infrastructure review
  • Sister-tenant comparison showing borrowed factory/lab imagery and replicated page timing
  • Contact-page and backend captures showing placeholder agents and empty support integrations
  • Payment-rail review covering card, crypto, and Inflyway artifacts

Risk assessment

  • Corporate/legal-authority risk — high: Site-linked Shenzhen Maidihao Trading Co., Ltd. is recorded as revoked and electronics-only in scope, with no peptide or pharmaceutical authorization.
  • Cloaked payment and storefront risk — high: Maidihao tenant 477 runs on Shop910, which advertises cloak, AB-redirect rotation, and special-goods card-processing tools for restricted gray-market commerce.
  • Replicated-network and deceptive facility-claims risk — high: Maidihao loads factory/lab images from sister tenant peptidetai.com (tenant 274) and shares template creation timestamps; no verifiable Maidihao facility is shown.
  • Customer-support and authentication risk — high: The contact page used placeholder WhatsApp +86 123456789 and 13456789@gmail.com for all agents, with empty chat/email integrations and no official-channel or COA verification system.
  • Storefront availability and order-continuity risk — high: During the investigation peptide5b.it.com stopped serving the storefront and redirected to the Shop910 admin login, leaving fulfillment and after-sale continuity uncertain.
  • Tesamorelin product-quality risk — medium: Finnrick rates Maidihao Tesamorelin at 51.19% across 4 tests (3 pass / 1 fail), materially weaker than its Retatrutide record.